The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.
Between 18-64 years old and healthy
Not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with study drug pharmacokinetics
Willing to abstain from consuming dietary/herbal supplements and citrus juices for several weeks
Willing to abstain from cannabis/marijuana, hemp, and THC- and CBD-containing products for several weeks
Under 18 or over 64 years old
Taking medications or dietary/herbal supplements that can interfere with study drug pharmacokinetics
Have a major illness
Taking medication/supplements for a mineral deficiency
Crossover
Oregano
Dietary supplementOil of oregano administered as a softgel (180 mg).
Drug cocktail
DrugOral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
Midazolam Area under the plasma concentration vs. time curve (AUC) ratio
Ratio of the area under the plasma concentration vs. time curve of midazolam in the presence to absence of oregano.
Caffeine AUC ratio
Area under the plasma concentration vs. time curve of caffeine in the presence to absence of oregano.
Caffeine maximum plasma concentration (Cmax) ratio
Ratio of the maximum plasma concentration of caffeine in the presence to absence of oregano.
Caffeine half-life ratio
Ratio of the half-life of caffeine in the presence to absence of oregano.
Dextromethorphan AUC ratio
Area under the plasma concentration vs. time curve of dextromethorphan in the presence to absence of oregano.
Click on the lead sponsor to view all of their trials.
Washington State University
Lead sponsor
Office of Dietary Supplements (ODS)
Collaborator
National Center for Complementary and Integrative Health (NCCIH)
Collaborator
